Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer

por Mitsunaga, S, Ikeda, M, Shimizu, S, Ohno, I, Furuse, J, Inagaki, M, Higashi, S, Kato, H, Terao, K, Ochiai, A
Publicado 2013

A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer

por Ikeda, M, Okusaka, T, Ito, Y, Ueno, H, Morizane, C, Furuse, J, Ishii, H, Kawashima, M, Kagami, Y, Ikeda, H
Publicado 2007

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

por Okusaka, T, Nakachi, K, Fukutomi, A, Mizuno, N, Ohkawa, S, Funakoshi, A, Nagino, M, Kondo, S, Nagaoka, S, Funai, J, Koshiji, M, Nambu, Y, Furuse, J, Miyazaki, M, Nimura, Y
Publicado 2010

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

por Ikeda, M., Shimizu, S., Sato, T., Morimoto, M., Kojima, Y., Inaba, Y., Hagihara, A., Kudo, M., Nakamori, S., Kaneko, S., Sugimoto, R., Tahara, T., Ohmura, T., Yasui, K., Sato, K., Ishii, H., Furuse, J., Okusaka, T.
Publicado 2016

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

por Matsuyama, Masato, Ishii, H., Furuse, J., Ohkawa, S., Maguchi, H., Mizuno, N., Yamaguchi, T., Ioka, T., Ajiki, T., Ikeda, M., Hakamada, K., Yamamoto, M., Yamaue, H., Eguchi, K., Ichikawa, W., Miyazaki, M., Ohashi, Y., Sasaki, Y.
Publicado 2014

Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer

por Ioka, T, Komatsu, Y, Mizuno, N, Tsuji, A, Ohkawa, S, Tanaka, M, Iguchi, H, Ishiguro, A, Kitano, M, Satoh, T, Yamaguchi, T, Takeda, K, Kida, M, Eguchi, K, Ito, T, Munakata, M, Itoi, T, Furuse, J, Hamada, C, Sakata, Y
Publicado 2017

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

por Lencioni, R, Kudo, M, Ye, S-L, Bronowicki, J-P, Chen, X-P, Dagher, L, Furuse, J, Geschwind, J F, de Guevara, L Ladrón, Papandreou, C, Takayama, T, Yoon, S K, Nakajima, K, Lehr, R, Heldner, S, Sanyal, A J
Publicado 2014

A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer(†)

por Ueno, M., Okusaka, T., Omuro, Y., Isayama, H., Fukutomi, A., Ikeda, M., Mizuno, N., Fukuzawa, K., Furukawa, M., Iguchi, H., Sugimori, K., Furuse, J., Shimada, K., Ioka, T., Nakamori, S., Baba, H., Komatsu, Y., Takeuchi, M., Hyodo, I., Boku, N.
Publicado 2016

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

por Okusaka, Takuji, Miyakawa, H., Fujii, H., Nakamori, S., Satoh, T., Hamamoto, Y., Ito, T., Maguchi, H., Matsumoto, S., Ueno, H., Ioka, T., Boku, N., Egawa, S., Hatori, T., Furuse, J., Mizumoto, K., Ohkawa, S., Yamaguchi, T., Yamao, K., Funakoshi, A., Chen, J. S., Cheng, A. L., Sato, A., Ohashi, Y., Tanaka, M.
Publicado 2017